Checkpoint Inhibitor

Cambridge, UK — August 17, 2026 AstraZeneca announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig...

MILLBRAE, Calif., August 11, 2026 Eikon Therapeutics announced the selection of a 0.60 mg/m² dose of EIK1001 for patients...

SAN DIEGO, July 20, 2026 Oncolytics Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast...

SAN DIEGO – May 8, 2026 Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...

Kenilworth, N.J., October 29, 2025— Merck & Co., Inc. (NYSE: MRK), known as MSD outside the U.S. and Canada,...